- The report contains detailed information about Cybrdi, Inc. that gives an unrivalled in-depth knowledge about internal business-environment of the company: data about the owners, senior executives, locations, subsidiaries, markets, products, and company history.
- Another part of the report is a SWOT-analysis carried out for Cybrdi, Inc.. It involves specifying the objective of the company's business and identifies the different factors that are favorable and unfavorable to achieving that objective. SWOT-analysis helps to understand company’s strengths, weaknesses, opportunities, and possible threats against it.
- The Cybrdi, Inc. financial analysis covers the income statement and ratio trend-charts with balance sheets and cash flows presented on an annual and quarterly basis. The report outlines the main financial ratios pertaining to profitability, margin analysis, asset turnover, credit ratios, and company’s long-term solvency. This sort of company's information will assist and strengthen your company’s decision-making processes.
- In the part that describes Cybrdi, Inc. competitors and the industry in whole, the information about company's financial ratios is compared to those of its competitors and to the industry. The unique analysis of the market and company’s competitors along with detailed information about the internal and external factors affecting the relevant industry will help to manage your business environment. Your company’s business and sales activities will be boosted by gaining an insight into your competitors’ businesses.
- Also the report provides relevant news, an analysis of PR-activity, and stock price movements. The latter are correlated with pertinent news and press releases, and annual and quarterly forecasts are given by a variety of experts and market research firms. Such information creates your awareness about principal trends of Cybrdi, Inc. business.
About Cybrdi, Inc.
Cybrdi, Inc., through its subsidiary, Shaanxi Chao Ying Biotechnology Co., Ltd., engages in the research, development, and manufacture of biotechnology products in the Peoples Republic of China.
Tissue Microarrays (TMA)
TMA technology would survey various clinical specimens in a single experiment utilizing common probes, including DNA, RNA, peptide, protein, and antibody probes. TMA chips would be applied in both basic and clinical research conducted by the academic, medical, pharmaceutical, and biogenetic research communities. It offers various tissue array products and services on the commercial market, including approximately 234 different disease and 98 different organ types of both human and animal varieties.
Complementing the production and marketing of tissue chips, the company has launched an in-house technical services platform to perform customized research according to customer specifications. Its technical services include the standard immunohisto chemistry (IHC) and in-situ-hybridization (ISH) services needed to locate proteins or genes of interest using customer-supplied probes.
Culture, Entertainment, and Real Estate Business
Shaanxi Chao Ying Biotechnology Co., Ltd. (Chaoying Biotech) owns 83.33% of Shandong Chaoying Culture and Entertainment Co., Ltd. (SD Chaoying), which is a culture and entertainment company with a special license for casino gambling. SD Chaoying is developing a culture and entertainment square in Changle City of Shangdong Province on the 33,333 square meter land it owns. With the entertainment facilities of restaurants spas, hotel rooms, movie theaters, cosmetic, and personal care salons, body buildup gyms, the square would become local cultural and entertainment center. The facility construction project annexed with 4 multi-family residential buildings (approximately 14,188 square meters), and 2 of them had been completed and some of the housing units had been sold.
The company has marketed TMA products, medical care products, and other services within the Chinese market. There are two primary regions in China where it focuses its marketing: the northern provinces which include the cities of Beijing, Tian Jing, and Hebei Province; and the eastern provinces which include the cities of Shanghai, Jiangsu, Guangdong, Fujian, Shanxi, Hunan, Hubei, Zhejiang Province, and Shangdong Province.
Through BioMax Ltd., the company has built up its sales channels in the United States, Canada, Germany, Italy, Belgium, Japan, and Taiwan.
The company supplies Biomax Ltd., a United States research and development subcontractor for Pfizer, and, through Biomax Ltd., it provides its products and services to other biotechnology companies in the U.S. and Europe, such as America Nanoarray. It also operates as a supplier for the Chinas National Biomedical Center, Shanghai Biochip Center, a research partner with Peking University Academy of Military Medical Sciences, and performs dermatological research and development for Lancome and Estee Lauder. In 2010, the companys domestic sales representative in China would be Xian AiLiNa Biotechnology Co., Ltd., and the overseas sales representative would be Biomax Ltd.
Cybrdi, Inc. was founded in 2000.
The above Company Fundamental Report is a half-ready report and contents are subject to change.
It means that we have all necessary data in our database to prepare the report but need 2-3 days to complete it. During this time we are also updating the report with respect to the current moment. So, you can get all the most recent data available for the same price. Please note that preparation of additional types of analyses requires extra time.
1. CYBRDI, INC. COMPANY PROFILE
1.2. Financial Performance
1.3. Key Executives
1.4. Ownership and Major Holders
1.5. Company History
2. CYBRDI, INC. BUSINESS OVERVIEW
2.2. Major Products and Services
2.3. Markets and Sales Activities
2.4. Locations, Subsidiaries, Operating Units
3. CYBRDI, INC. SWOT ANALYSIS
4. CYBRDI, INC. FINANCIAL ANALYSIS
4.1.1. Income Statement
4.1.2. Balance Sheet
4.1.3. Cash Flow
4.2. Financial Ratios
4.2.2. Margin Analysis
4.2.3. Asset Turnover
4.2.4. Credit Ratios
4.2.5. Long-Term Solvency
4.2.6. Growth Over Prior Year
4.2.7. Financial Ratios Charts
4.3. Stock Market Snapshot
5. CYBRDI, INC. COMPETITORS AND INDUSTRY ANALYSIS
5.1. Cybrdi, Inc. Direct Competitors
5.2. Comparison of Cybrdi, Inc. and Direct Competitors Financial Ratios
5.3. Comparison of Cybrdi, Inc. and Direct Competitors Stock Charts
5.4. Cybrdi, Inc. Industry Analysis
5.4.1. Pharmaceuticals and Biotechnology Industry Snapshot
5.4.2. Cybrdi, Inc. Industry Position Analysis
6. CYBRDI, INC. NEWS & EVENTS
6.1. News & PR Activity Analysis
6.2. IR Corporate News
6.3. Marketing News
6.4. Corporate Events
7. CYBRDI, INC. EXPERTS REVIEW1
7.1. Experts Opinion
7.2. Experts Estimates
8. CYBRDI, INC. ENHANCED SWOT ANALYSIS2
9. CHINA PESTEL ANALYSIS2
9.2. Economic Factors
9.3. Social Factors
9.4. Technological Factors
9.5. Environmental Factors
9.6. Legal Factors
10. CYBRDI, INC. IFE, EFE, IE MATRICES2
10.2. External Factor Evaluation Matrix
10.3. Internal External Matrix
11. CYBRDI, INC. PORTER FIVE FORCES ANALYSIS2
12. CYBRDI, INC. VRIO ANALYSIS2
APPENDIX: RATIO DEFINITIONS
LIST OF TABLES
Cybrdi, Inc. Key Facts
Income Statement Key Figures
Balance Sheet Key Figures
Cash Flow Statement Key Figures
Financial Performance Abbreviation Guide
Cybrdi, Inc. Key Executives
Key Executives Biographies1
Key Executives Compensations1
Cybrdi, Inc. Major Shareholders
Cybrdi, Inc. History
Cybrdi, Inc. Products
Revenues by Segment
Revenues by Region
Cybrdi, Inc. Offices and Representations
Cybrdi, Inc. SWOT Analysis
Yearly Income Statement Including Trends
Income Statement Latest 4 Quarters Including Trends
Yearly Balance Sheet Including Trends
Balance Sheet Latest 4 Quarters Including Trends
Yearly Cash Flow Including Trends
Cash Flow Latest 4 Quarters Including Trends
Cybrdi, Inc. Profitability Ratios
Margin Analysis Ratios
Asset Turnover Ratios
Long-Term Solvency Ratios
Financial Ratios Growth Over Prior Year
Cybrdi, Inc. Capital Market Snapshot
Cybrdi, Inc. Direct Competitors Key Facts
Direct Competitors Profitability Ratios
Direct Competitors Margin Analysis Ratios
Direct Competitors Asset Turnover Ratios
Direct Competitors Credit Ratios
Direct Competitors Long-Term Solvency Ratios
Pharmaceuticals and Biotechnology Industry Statistics
Cybrdi, Inc. Industry Position
Company vs. Industry Income Statement Analysis
Company vs. Industry Balance Sheet Analysis
Company vs. Industry Cash Flow Analysis
Company vs. Industry Ratios Comparison
Cybrdi, Inc. Consensus Recommendations1
Analyst Recommendation Summary1
Price Target Summary1
Experts Recommendation Trends1
Revenue Estimates Analysis1
Earnings Estimates Analysis1
Revenue Estimates Trend1
Earnings Estimates Trend1
LIST OF FIGURES
Cybrdi, Inc. Annual Revenues in Comparison with Cost of Goods Sold and Gross Profit
Profit Margin Chart
Operating Margin Chart
Return on Equity (ROE) Chart
Return on Assets (ROA) Chart
Debt to Equity Chart
Current Ratio Chart
Cybrdi, Inc. 1-year Stock Charts
Cybrdi, Inc. 5-year Stock Charts
Cybrdi, Inc. vs. Main Indexes 1-year Stock Chart
Cybrdi, Inc. vs. Direct Competitors 1-year Stock Charts
Cybrdi, Inc. Article Density Chart
2 – These sections are available only when you purchase a report with appropriate additional types of analyses.
The complete financial data is available for publicly traded companies.
Enhanced SWOT Analysis
- How to use the strengths to take advantage of the opportunities?
- How to use the strengths to reduce likelihood and impact of the threats?
- How to overcome the weaknesses that obstruct taking advantage of the opportunities?
- How to overcome the weaknesses that can make the threats a reality?
Key Factors Examined by PESTEL Analysis:
- Legal – What laws and legislation will exert influence on the style the business is carried out?
IFE, EFE, IE Matrices
Porter Five Forces Analysis
- What composes a threat of substitute products and services?
- Is there a threat of new competitors entering the market?
- What is the intensity of competitive rivalry?
- How big is the bargaining power of buyers?
- How significant is the bargaining power of suppliers?
- Tangible resources
- Intangible resources
- Innovation and Creativity
- Organizational capabilities
- Costly to imitate?
- Organized properly?